<div id="readability-page-1"><h3>Claim 30% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Everest Medicines Ltd. ( (HK:1952) ) has issued an announcement. Everest Medicines Limited has released its audited annual results for the year ended 31 December 2025, confirming that the full 2025 annual report is now available in both Chinese and English. The results, reviewed by the audit committee and Ernst &amp; Young, will be accessible online, with printed reports delivered to shareholders and electronic versions posted by the end of April 2026, reinforcing the company’s compliance and transparency obligations under Hong Kong listing rules. The most recent analyst rating on (HK:1952) stock is a Hold with a HK$36.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page. More about Everest Medicines Ltd. Everest Medicines Limited is a biopharmaceutical company listed on the Hong Kong Stock Exchange, focusing on the development and commercialization of innovative medicines. The group operates through a network of subsidiaries and is overseen by a board comprising executive, non-executive and independent non-executive directors based in Hong Kong and the Cayman Islands. Average Trading Volume: 3,174,542 Technical Sentiment Signal: Sell Current Market Cap: HK$12.47B For an in-depth examination of 1952 stock, go to TipRanks’ Overview page.</div>

516820

159837

512290

Everest Medicines Ltd. has published its audited annual results for the year ending December 31, 2025. The full report is available in Chinese and English, with printed copies to be sent to shareholders by April 2026. The results were reviewed by Ernst & Young and comply with Hong Kong listing rules. The current analyst rating for Everest Medicines (HK:1952) is a Hold, with a price target of HK$36.00. The company focuses on developing innovative biopharmaceuticals and has a market cap of HK$12.47B.

Tip Ranks

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Tianhong CNI BIOMEDICINE ETF

Yinhua CSI Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

EVEREST MED

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

Huaan Hang Seng Biotech ETF

ChinaAMC CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CNI HK Connect Innovative Drugs ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Everest Medicines Publishes Audited 2025 Annual Results and Report